FDA PABOR NA MAGKAROON ANG PUBLIKO NG PAGPIPILIANG BAKUNA KONTRA COVID-19

Ni Monica N. Ladisla
Source: PNA
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Inihayag ng Food and Drug Administration (FDA) na mas mabuti umanong may pagpipilian ang publiko pagdating sa bakunang nais nilang gamitin sapagkat inaasahang may negatibong epekto ang ilang bakunang paparating sa bansa.

“For each and every patient you have to find a better vaccine for you and not one vaccine is probably good for everybody so it’s good to have a basket of choices.”

Ayon kay FDA Director General Eric Domingo, maaari umanong hindi maging compatible ang bakunang gawa ng Pfizer at Moderna sa mga indibidwal na mayroong severe allergies.

“The mRNA vaccine is completely laboratory-synthesized. That’s why they can do it a lot weaker and cheaper. There’s this possibility of getting an allergic reaction, possible severe allergic reaction so ‘yun talaga ang we have to watch out for. ‘Pag meron ka severe allergy maybe this is not for you,” pahayag ni Domingo.

Nakatakda rin umanong maglabas ng listahan ang FDA ng mga bakunang nabigyan ng emergency use authorization (EUA) upang maikonsulta ng publiko sa kani-kanilang mga doktor ang mga posibleng sangkap ng bawat bakuna na maaaring maging sanhi ng allergic reaction.

Sa kasalukuyan, mayroon nang emergency use authorization sa bansa ang bakunang gawa ng Pfizer at AstraZeneca. Sinusuri pa ng FDA ang EUA application ng Sinovac, Bharat Biotech mula sa India, at Gamaleya ng bansang Russia.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.